Comparison of the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxalipla-tin in the treatment of recurrent platinum-resistant ovarian cancer
10.3760/cma.j.issn.1673-422X.2019.01.007
- VernacularTitle:脂质体多柔比星单药与吉西他滨联合 奥沙利铂对复发性铂耐药卵巢癌患者的疗效及安全性比较
- Author:
Chaonan CHU
1
;
Qi HUANG
Author Information
1. 湖南省肿瘤医院 中南大学湘雅医学院附属肿瘤医院妇瘤四科
- Keywords:
Ovarian neoplasms;
Treatment outcome;
Doxorubicin
- From:
Journal of International Oncology
2019;46(1):32-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate and compare the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum-resistant ovarian cancer. Methods From January 1,2015 to December 31,2016,80 patients from Hunan Cancer Hospital with recurrent platinum-resistant ovarian cancer were divided into two groups by using random number table method,40 cases in each group:group PLD was treated with liposome doxorubicin and group G/ O was treated with gemcitabine combined with oxaliplatin. The therapeutic effects of the two groups were evaluated,the expressions of CA125 after treat-ment were compared and the occurrence of adverse reactions were observed. Results The objective response rate(ORR)and disease control rate(DCR)were respectively 27. 5％(11 / 40)and 35. 0％(14 / 40)in group PLD,and the ORR and DCR were respectively 22. 5％(9 / 40)and 27. 5％(11 / 40)in group G/ O,and there was no significant difference between the two groups(χ2 = 0. 27,P = 0. 61;χ2 = 0. 52,P = 0. 47). In PLD group and G/ O group,the CA125 values of ORR patients were(61. 27 ±28. 11)U/ ml and(78. 29 ± 34. 26)U/ ml respectively,with no significant difference(t = 1. 22,P = 0. 24),the CA125 values of non ORR patients were (530. 07 ± 77. 15)U/ ml and(551. 00 ± 78. 78)U/ ml respectively,with no significant difference(t = 1. 04, P = 0. 30). The main adverse reactions in group PLD were hand foot syndrome and myelosuppression. The main adverse reactions in group G/ O were gastrointestinal reaction and myelosuppression. The incidence rates of leucocyte reduction(65. 0％ vs. 92. 5％ ,χ2 = 9. 04,P = 0. 005),thrombopenia(15. 0％ vs. 52. 5％ ,χ2 = 12. 58,P < 0. 001),anemia(15. 0％ vs. 40. 0％ ,χ2 = 6. 27,P = 0. 012),gastrointestinal reaction (17. 5％ vs. 60. 0％ ,χ2 = 15. 22,P < 0. 001)and neurotoxicity(5. 0％ vs. 30. 0％ ,χ2 = 8. 66,P = 0. 006) in group PLD were lower than those in group G/ O,with significant differences. Conclusion The efficacy of two chemotherapy regimens is similar in patients with recurrent platinum-resistant ovarian cancer. Liposome doxorubicin has less adverse reactions than gemcitabine combined with oxaliplatin.
